The Future of US Pharma: Dr. Reddy's CEO Predicts Biosimilars to Eclipse Generics by Early 2030s
The Pharmaceutical Frontier: Biosimilars on the Rise
The Big Play: Dr. Reddy's Bets on a Trio of Launches to Outmaneuver US Market Erosion